Neurana Pharmaceuticals

Please note: The information displayed on this page might be outdated.
Neurana Pharmaceuticals: Neurana Pharmaceuticals is a clinical stage, private biotechnology company developing tolperisone, a novel, non-opioid treatment for acute and painful muscle spasms without drowsiness or impact on cognitive function.

Neurana has completed a Phase 1 clinical study which confirmed the non-sedative properties of tolperisone using a driving simulation study. Neurana announced on September 23rd, 2019 the positive topline results from the “STAR Study”, a Phase 2 dose-ranging study of tolperisone in acute muscle spasms of the back. The primary objective of the study was to assess the efficacy of various daily doses of tolperisone to determine the dose to be used for the planned Phase 3 clinical program. Overall, the STAR Study demonstrated the efficacy of tolperisone with the 600 mg dose being highly significant (p=0.004) with sleepiness similar to placebo.

Given the positive results of the STAR Study, Neurana plans to conduct an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 and initiate Phase 3 clinical studies of tolperisone later in 2020. The company has Composition of matter and process patents that have been issued by the US Patent and Trademark Office (USPTO) providing Orange Book listable patent protection through 2032.
Based in...
US - Pacific
Clinical Stage
Phase III
Disease Space
Central Nervous System, Pain
Market Cap
4370 La Jolla Village Drive
Suite 860
San Diego, CA 92122
United States

Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13

  • Craig Thompson, President & CEO